Ghrelin, the only known peripherally produced and centrally acting peptide that stimulates food intake, is synthesized primarily in the stomach and acts through the growth hormone secretagogue receptor (GHS-R1a). In addition to its orexigenic effect, ghrelin stimulates the release of growth hormone (GH). In this study, we investigated the biological properties of fulllength and shortened ghrelin analogs in which octanoylated Ser 3 is replaced with an octanoic acid moiety coupled to diaminopropionic acid (Dpr). Ghrelin analogs stabilized with Dpr(N-octanoyl) in position 3 and noncoded amino acids in position 1 (sarcosine) and/or position 4 (naphthylalanine or cyclohexylalanine) were found to possess affinities similar to those of ghrelin for cell membranes with transfected GHS-R1a. In vivo, the prolonged orexigenic effects of analogs containing Dpr(N-octanoyl) 3 compared with that of ghrelin in adult mice and a similar impact on GH secretion in young mice were found. Full-length [Dpr(N-octanoyl) 3 ]ghrelin and its analogs with a noncoded amino acid in position 1 and/or 4 showed significantly prolonged stability in blood plasma compared with that of ghrelin. Ghrelin analogs with a prolonged orexigenic effect are potential treatments for GH deficiency or cachexia that accompanies chronic diseases. Desoctanoylated ghrelin analogs and N-terminal penta-and octapeptides of ghrelin did not show any biological activity.
Introduction
Ghrelin is the only known hormone synthesized in the gut and acting centrally that possesses an orexigenic effect (for reviews, see Depoortere, 2009; Castañ eda et al., 2010; Wisser et al., 2010; Briggs and Andrews, 2011; Nass et al., 2011; Scerif et al., 2011) . In the adenohypophysis, ghrelin releases Ca 2ϩ from intracellular stores that stimulates and amplifies pulsatile secretion of growth hormone (GH) (Smith et al., 1997) . Therefore, the term growth hormone secretagogue receptor (GHS-R1a) is used for the ghrelin receptor. In the arcuate nucleus of the hypothalamus, ghrelin implements its orexigenic effect in neurons that express the most powerful neuropeptide, orexigenic neuropeptide Y (Kohno et al., 2003) .
Ghrelin is the only hormone containing a serine acylated with n-octanoic acid, which is necessary for its biological activity (Kojima et al., 1999) . The ester bond of Ser 3 is hydrolyzed easily by esterases in the blood; therefore, only 10 to 20% of circulating ghrelin is octanoylated (Depoortere, 2009 ).
Although octanoylation is necessary for ghrelin's biological activity, the link between octanoic acid and ghrelin can be modified. When octanoic acid was connected to the peptide backbone of ghrelin by an amide (Bednarek et al., 2000) , thioether, or ether bond (Matsumoto et al., 2001a) , neither the binding potency nor the calcium release in the cells with transfected GHS-R1a was affected.
In vitro structure-activity studies in cells that overexpress the ghrelin receptor reveal that an N-terminal tetrapeptide with an octanoyl group in position 3 is the minimal core of ghrelin that is necessary for biological activity (Bednarek et al., 2000; Matsumoto et al., 2001a,b; Torsello et al., 2002 ). An alanine scan of 14 amino acids at the N terminus of ghrelin showed that, in addition to octanoylation at position 3, an N-terminal positive charge and Phe 4 are essential for the biological activity of ghrelin (Van Craenenbroeck et al., 2004) . However, the C-terminal part of ghrelin was shown to be important for the stability of ghrelin in in vivo testing (Morozumi et al., 2011) .
On the basis of the structure-activity studies mentioned above, ghrelin analogs with potentially enhanced stability were designed in this study. Initially, ghrelin was modified by replacing the serine in position 3 with diaminopropionic acid (Dpr), which can form a stable amide bond with octanoyl acid [Dpr(N-octanoyl)] (according to Bednarek et al., 2000) and protect the molecule from hydrolysis by esterases. Subsequently, N-terminal glycine and Phe 4 were replaced with noncoded amino acids to protect the analogs against the activity of aminopeptidases or chymotrypsin-like proteinases, respectively. The designed analogs of ghrelin were examined for their affinities to cell membranes with transfected GHS-R1a (Guerlavais et al., 2003) , orexigenic effects in adult mice, GH secretagogue activities in young mice, and stabilities in blood plasma. In addition, desoctanoylated and shorter N-terminal analogs of ghrelin were tested similarly in the hope of obtaining a shorter active ghrelin analog.
We aimed to design peptidic ghrelin agonists with a biological activity similar to and a higher stability than ghrelin. Such substances could have a prolonged effect in the treatment of cachexia and sarcopenia.
Materials and Methods

Synthesis of Peptides.
Mouse ghrelin (ghr) [Gly-Ser-Ser(Ooctanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-His-Gln-Lys-Ala-Gln-Gln-ArgLys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg], [Dpr(Noctanoyl) 3 ]ghrelin ([Dpr 3 ]ghr), their full-length analogs with a C-terminal COOH, and N-terminal penta-and octapeptides amidated at the C terminus (Table 1) were assembled in a solid-phase ABI433A synthesizer (Applied Biosystems, Foster City, CA) by stepwise coupling of the corresponding fluorenylmethyloxycarbonyl amino acids to the growing chain on Rink amide resin (1% divinylbenzene, 200 -400 mesh, 0.65 mmol/g) or Wang resin (1% divinylbenzene, 100 -200 mesh, 0.57 mmol/g) (both from IRIS Biotech GmbH, Marktredwitz, Germany). The fully protected peptides were synthesized, and the peptides were purified and analyzed according to a standard procedure (Maixnerová et al., 2007) . Octanoylation of Ser 3 and Dpr 3 was performed using a trityl group to protect the side chain of Ser 3 and a methyltrityl group to protect the side chain of Dpr 3 , as described in the literature (Bednarek et al., 2000) .
Ghrelin and [Dpr 3 ]ghr were iodinated at His 9 with either Na[ 125 I] or nonradioactive NaI using IODO-GEN (Thermo Fisher Scientific, Waltham, MA)-coated Eppendorf tubes according to a published procedure (Elbert and Veselá , 2010) . The purification was accomplished on an Agilent Prep-C18 5 column (250 ϫ 4.6 mm) (Agilent Technologies, Santa Clara, CA), a gradient elution from 10% B to 20% B over 5 min and next to 30% B in 60 min (A ϭ water with 0.1% trifluoroacetic acid, B ϭ acetonitrile with 0.1% of trifluoroacetic acid). The nonradioactive iodinated peptides were used as the control for molecular weights using MALDI-TOF Reflex IV mass spectrometry (Bruker Daltonics, Billerica, MA Receptor Binding Studies. Binding studies were performed as described in the literature (Guerlavais et al., 2003) . In brief, isolated plasma membranes from LLC PK-1 cells with transfected human GHS-R1a (10 g of protein per tube) were used. Cell membranes were incubated with 0. 125 I]ghr and 1 pM to 0.1 mM nonradioactive ligand in competitive binding experiments. Incubations were performed in a total volume of 0.5 ml of binding buffer (50 mM Tris/HCl, 5 mM EDTA, 2.5 mM MgCl 2 , and 0.1% bovine serum albumin) for 45 min at 25°C. Nonspecific binding was determined in the presence of 10 M ghrelin. The binding reaction was stopped by the addition of ice-cold washing buffer [20 mM Tris (pH 7.4), 5 mM EDTA, 2.5 mM MgCl 2 , and 0.015% Triton 20] followed by rapid filtration over GF/C filters (Whatman, Clifton, NJ) presoaked with 0.5% polyethyleneimine using a Brandel cell harvester (Brandel Inc., Gaithersburg, MD). Filters were rinsed subsequently three times with ice-cold washing buffer. Bound radioactivity was determined by gamma counting (Wizard 1470 Automatic Gamma Counter; PerkinElmer Life and Analytical Sciences, Waltham, MA). Nonspecific binding amounted to Ͻ15% of the total binding. Experiments were carried out in duplicate at least three times.
Experimental Animals. All of the experiments followed the ethical guidelines for animal experiments and Czech Republic law 246/ 1992 and were approved by the committee for experiments with laboratory animals of the Academy of Sciences of the Czech Republic.
Inbred C57BL/6 male mice (AnLab, Prague, Czech Republic) were housed at a temperature of 23°C under a daily cycle of 12 h of light and dark (light from 6:00 AM) with free access to water and a standard chow diet that contained 25%, 9%, and 66% of calories from protein, fat, and carbohydrate, respectively. The energy content of the diet was 3.4 kcal/g (St-1; Mlýn Kocanda, Jesenice, Czech Republic).
Effect of Ghrelin Analogs on Food Intake. Twelve-week-old mice were placed into separate cages for 1 week with free access to water and food pellets. For the evaluation of the orexigenic activity of Xxx-Ser-Yyy-Zzz-Leu-Ser-Pro-Glu-His-Gln-His-Gln-Lys-Ala-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg. Mean Ϯ S.E.M. of at least three separate experiments. K i was calculated using the Cheng-Prusoff equation (Cheng and Prusoff, 1973 ) (K d ϭ 0.44 Ϯ 0.12 nM from the saturation binding experiment). For the calculation of ED 50 Ϯ S.E.M., food intake 250 min after the subcutaneous administration of analogs in doses of 0.1 to 10 mg/kg (maximal effect) was examined. n ϭ 5-6 mice per group. No effect NT, not tested.
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peptides, mice were fed freely before the experiment. Anorexigenic activity was tested in mice that fasted for 17 h. The experiment started at 8:00 AM, and mice were injected subcutaneously with 0.2 ml of saline or the tested compounds (dissolved in saline) at a dose of 0.1 to 10 mg/kg (n ϭ 5-6 mice per group). Fifteen minutes after the injection, mice were given preweighed food pellets. Food intake was followed for 6 h. The pellets were weighed at 30-min intervals and then returned to the cage, and cumulative food intake was registered. Animals had free access to water during the experiments. GH Assay. The effects of selected ghrelin analogs on GH release was determined in 6-week-old male C57BL/6 mice. At 8:00 AM, fed mice were injected subcutaneously with 0.2 ml of the tested compounds (dissolved in saline) at a dose of 5 mg/kg (n ϭ 4 -5 mice per group). Ten or 30 min after the injection, blood was collected, and the plasma was separated and stored at Ϫ20°C until being used. GH in the plasma samples was determined with a radioimmunoassay kit (IZOTOP, Budapest, Hungary) according to the protocol recommended by the manufacturer.
Degradation of Ghrelin Analogs by Mouse Plasma. Ghrelin and selected ghrelin analogs at a concentration of 1 M in plasma from 12-week-old mice were incubated at 37°C for various time periods. Incubation was stopped by quick freezing to Ϫ20°C. After being thawed, samples were kept at 4°C throughout the following procedures. They were filtered through YM-10 ultrafiltration membranes (Millipore Corporation, Billerica, MA) by centrifugation at 4°C for 20 min at 16,000 x g. The filters were washed three times with 0.1% formic acid, and the filtrates were lyophilized subsequently. The samples were reconstituted with 0.1% formic acid up to the original volume of plasma for subsequent liquid chromatography-mass spectrometry (LC-MS) analysis. Chromatographic separation was achieved on an ACQUITY UPLC BEH C18 column (2.1 ϫ 150 mm), packed with 1.7-m particles (Waters, Milford, MA). The sample injection volume was 10 l. The separation was performed using a linear gradient of 95% solvent A in solvent B to 100% solvent B over 20 min [solvent A consisted of H 2 O/acetonitrile, 98:2 (v/v), with 0.1% formic acid; solvent B was acetonitrile]. The flow rate was 100 l/min and was generated with a Rheos 2200 pump system (Flux Instruments, Reinach, Switzerland) equipped with an HTS-PAL autosampler (CTC Analytics AG, Zwingen, Switzerland). Mass detection was performed using an LTQ Orbitrap mass spectrometer (Thermo Fisher Scientific) using electrospray ionization in positive mode. Electrospray ionization parameters were as follows: sheath gas flow rate, 25 arb; auxiliary gas flow rate, 5 arb; capillary temperature, 275°C; capillary voltage, 40 V; tube lens, 155 V; and ion spray voltage, 4.3 kV. All of the samples were run in duplicate.
Statistical Analysis. The data are presented as the mean Ϯ S.E.M. Saturation and competitive binding curves were plotted using GraphPad software (GraphPad Software Inc., San Diego, CA) while comparing the best fit for single binding site models (K d , B max , and IC 50 values were obtained from nonlinear regression analysis). Inhibition constants (K i ) were calculated from IC 50 values using the Cheng-Prusoff equation (Chang and Cheng, 1978) .
Food intake was measured in grams of chow consumed, and the ED 50 values were calculated using GraphPad Software as the dose of the peptide required to elicit half-maximal consumption at 250 min after the injection of the compound (time of maximal effect).
Data from GH release and from food intake experiments were analyzed by one-way analysis of variance followed by Dunnett's post hoc test using GraphPad Software; p Ͻ 0.05 was considered statistically significant.
Results
Design and Synthesis of Ghrelin Analogs. The peptide sequences were assembled on a solid support as described under Materials and Methods. The purity of all of the peptides was Ͼ95%.
Structures of the ghrelin analogs used in this study are shown in Table 1 . The ester group of the amino acid in position 3 was replaced with an amide group to increase the stability (Bednarek et al., 2000) in the series of [Dpr 3 ]ghr derivatives (compounds 2-7 and 9-12). To further increase the stability of the ghrelin peptide analogs, sarcosine was used to replace glycine at the N-terminal position (analogs 3, 5, 7, 10, and 12), and/or the noncoded amino acids naphthylalanine (Nal) (analogs 4 and 5) and cyclohexylalanine (Cha) (analogs 6 and 7) replaced phenylalanine at position 4. To find the minimal structure that retained biological activity, N-terminal penta-and octapeptide analogs of ghrelin (8 -12) were synthesized. Pentapeptides 13 and 14 are shorter versions of full-length ghrelin in which Trp 3 or Nal 3 replace Ser(O-octanoyl) 3 . These analogs were found by others (Matsumoto et al., 2001a) (Fig. 1) . The results of competitive displacement of [
125 I]ghr binding by ghrelin analogs are summarized in Table 1 . Ghrelin and its full-length analogs 2 to 8 had K i values in the nanomolar range. The K i values for analogs 4 and 5, which contained Nal in position 4, were even lower, in the 0.1 nM range. The N-terminal pentapeptides 8 and 9 and octapeptide 12 showed K i values in the micromolar range (Table 1) 125 I]ghr (M. Pýchová, unpublished observations). In Vivo Studies. The effects of subcutaneously administered ghrelin analogs on food intake were tested in fed mice (orexigenic activity) or fasted mice (anorexigenic activity). None of the tested ghrelin analogs caused a decrease in food intake in fasted mice at a dose of 10 mg/kg compared with that of the saline-treated group (M. Holubová, unpublished observations).
On the contrary, full-length analogs of ghrelin showed a very significant orexigenic effect in freely fed mice at doses of 1 to 10 mg/kg s.c. compared with that of the control (Fig. 2) . In addition, the orexigenic effect of [Dpr 3 ]ghr analogs lasted longer than that of ghrelin and was even more pronounced in analogs containing noncoded amino acids (peptides 3, 4, and 6 with Sar in position 1 and Nal or Cha in position 4; Fig. 2 ). The ED 50 values when the maximal orexigenic effects were achieved at 250 min (Table 1) were in the range of mg/kg for all of the full-length analogs. The ED 50 value for subcutaneously administered ghrelin in this study was approximately 2 mg/kg, which is similar to that reported previously (Perreault et al., 2004) . On the contrary, penta-and octapeptide ghrelin analogs, desoctanoyl ghr, and desoctanoyl [Dpr 3 ]ghr did not show any significant orexigenic effect even at the maximum dose of 10 mg/kg (Table 1) .
A significant and comparable increase in the release of GH at a dose of 5 mg/kg was observed in 6-week-old male mice after the administration of ghrelin and the selected analogs [Dpr 3 ]ghr, [Dpr 3 ,Nal 4 ]ghr, and [Dpr 3 ,Cha 4 ]ghr (compounds 2, 4, and 6) both 10 and 30 min after treatment (Fig. 3) .
Degradation of Ghrelin Analogs by Mouse Plasma. Ghrelin was degraded rapidly in mouse plasma (Fig. 4) . However, [Dpr 3 ]ghr and its two analogs showed prolonged stability in mouse plasma of Ͼ4 h (Fig. 4) .
Discussion
Octanoylation of Ser 3 in ghrelin is unique in biological systems, and its necessity for the binding of ghrelin to its receptor and for biological activity was recognized soon after the discovery of ghrelin (Kojima et al., 1999; Bednarek et al., 2000) . Protection of the octanoyl group against the activity of esterases has been accomplished by replacing Ser 3 with Dpr. This change was found earlier to affect neither the binding activity nor calcium release from cells with transfected with GHS-R1a (Bednarek et al., 2000) . However, the in vivo properties of [Dpr 3 ]ghr have not been followed previous to our study. All of the full-length ghrelin analogs in this study were based on [Dpr 3 ]ghr. In the in vitro study, we confirmed similar affinities of ghrelin and [Dpr 3 ]ghr for GHS-R1a by obtaining similar K d values in saturation binding and equal K i values in competitive binding to cell membranes with transfected GHS-R1a.
In the in vivo experiments in adult mice, subcutaneously administered [Dpr 3 ]ghr exhibited an augmented and longerlasting orexigenic effect than that observed for ghrelin. The result corresponded with Ͼ4 h of stability of [Dpr 3 ]ghr in blood plasma. Ghrelin was degraded totally in blood plasma in only 40 min, as reported also by De Vriese et al. (2004) .
To protect [Dpr 3 ]ghr against degradation by aminopeptidases, glycine in position 1 was replaced with Sar according to our previous experience (Maletínská et al., 1997) , where ]ghr. Specific binding was calculated by subtracting the nonspecific binding from the total binding. Binding curves were plotted using nonlinear regression. The figure is a representative example of four experiments performed in duplicate. Fig. 2 . Effects of ghrelin analogs on food intake of fed mice. Compounds were administered subcutaneously at a dose of 5 mg/kg. Food intake was monitored for 6 h after the injection and is expressed in grams of food consumed. p Ͻ 0.05 (ghrelin versus saline-treated group); p Ͻ 0.01 ([ Sar Fig. 3 . Effects of ghrelin analogs on GH release. At 10 and 30 min after the subcutaneous injection of ghrelin analogs (at a dose of 5 mg/kg) to mice (n ϭ 4 -5), blood was collected, and GH was measured in blood plasma using a radioimmunoassay. ‫,ءء‬ p Ͻ 0.01; ‫,ءءء‬ p Ͻ 0.001 versus the respective control groups. 
